FDA Inspection
Halo Pharmaceutical, Inc. d/b/a Cambrex WhippanyHalo Pharmaceutical, Inc. d/b/a Cambrex Whippany – FDA Inspection, Mar 20, 2017
Record Details
This FDA Inspection record concerns Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany, with an inspection on March 20, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- March 20, 2017
- Product Type
- Drugs
View Company Profile
ID · 9a730984-8411-4cbd-89ee-7407053ace5a
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1008344
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
12| Date | Classification | Office | Project area |
|---|---|---|---|
| December 8, 2025 | Not classified | New Jersey District Office | |
| February 17, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 20, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 30, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 24, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
- FDA Inspection 1297650 - 2025-12-08
- FDA Inspection 1197680 - 2023-02-17
- FDA Inspection 1116333 - 2019-12-20
- FDA Inspection 1055544 - 2018-05-30
- FDA Inspection 1027562 - 2017-08-24
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.